MARKET

IPSC

IPSC

Century Therapeutics, Inc.
NASDAQ
2.250
-0.060
-2.60%
After Hours: 2.240 -0.01 -0.44% 19:35 07/10 EDT
OPEN
2.310
PREV CLOSE
2.310
HIGH
2.310
LOW
2.185
VOLUME
1.21M
TURNOVER
--
52 WEEK HIGH
3.040
52 WEEK LOW
0.4350
MARKET CAP
405.80M
P/E (TTM)
-2.0327
1D
5D
1M
3M
1Y
5Y
1D
Century: 'Hold' Based On CNTY-101 Pivot And CNTY-813 T1D Curative Potential
Seeking Alpha · 2d ago
Century Therapeutics to present CNTY-813 type 1 diabetes preclinical data at EASD 2026
PUBT · 2d ago
Weekly Report: what happened at IPSC last week (0629-0703)?
Weekly Report · 5d ago
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga · 06/30 12:03
Weekly Report: what happened at IPSC last week (0622-0626)?
Weekly Report · 06/29 09:15
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
Benzinga · 06/26 14:18
Weekly Report: what happened at IPSC last week (0615-0619)?
Weekly Report · 06/22 09:17
Century Therapeutics cuts CSO Chad Cowan salary to $296,150 under amended employment agreement
PUBT · 06/16 20:08
More
About IPSC
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.

Webull offers Century Therapeutics Inc stock information, including NASDAQ: IPSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPSC stock methods without spending real money on the virtual paper trading platform.